InvestorsHub Logo

joseytheoutlawwales

11/11/20 1:10 PM

#30280 RE: mantis #30266

You are correct that one cannot, and should not, infer results to a larger sample based upon a small cohort.

And it’s really not 94 patients.

85 placebo, 9 vaccine- of the 9; sample.

So they are basing their widely (globally) reported results on a 9 patient sample.

It’s actually clinically irresponsible IMO.

mikar

11/12/20 5:14 AM

#30332 RE: mantis #30266

Many unanswered questions remain about the vaccine:
“It’s also unknown whether any of the 94 coronavirus patients had underlying risk factors. That data matters because state and county officials are prioritizing high-riskand socially vulnerable groups during the first distribution waves. “It’s not clear in the trial who got the vaccine,” says Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia and a member of the FDA’S COVID-19 advisory committee. “You wonder whether those groups of people were adequately represented.”